RHHBY Quote, Financials, Valuation and Earnings

Eli Lilly and has a net margin of -- compared to Roche Holding AG's net margin of 21.68%. Roche Holding AG's return on equity of 23.8% beat Eli Lilly and's return on equity of 78.25%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 15.46%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Eli Lilly and has higher upside potential than Roche Holding AG, analysts believe Eli Lilly and is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.358% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.46%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Roche Holding AG's net income of -- is lower than Eli Lilly and's net income of $2.8B. Notably, Roche Holding AG's price-to-earnings ratio is 28.67x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Merck & has a net margin of -- compared to Roche Holding AG's net margin of 32.71%. Roche Holding AG's return on equity of 23.8% beat Merck &'s return on equity of 39.02%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 15.46%. On the other hand Merck & has an analysts' consensus of $101.79 which suggests that it could grow by 23.48%. Given that Merck & has higher upside potential than Roche Holding AG, analysts believe Merck & is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.358% less volatile than S&P 500. In comparison Merck & has a beta of 0.389, suggesting its less volatile than the S&P 500 by 61.063%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.46%. Merck & offers a yield of 3.88% to investors and pays a quarterly dividend of $0.81 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Merck & pays out 45.8% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Merck & quarterly revenues of $15.5B. Roche Holding AG's net income of -- is lower than Merck &'s net income of $5.1B. Notably, Roche Holding AG's price-to-earnings ratio is 28.67x while Merck &'s PE ratio is 12.00x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus 3.27x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

Novartis AG has a net margin of -- compared to Roche Holding AG's net margin of 26.48%. Roche Holding AG's return on equity of 23.8% beat Novartis AG's return on equity of 30.96%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 15.46%. On the other hand Novartis AG has an analysts' consensus of $113.44 which suggests that it could fall by -4.16%. Given that Roche Holding AG has higher upside potential than Novartis AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.358% less volatile than S&P 500. In comparison Novartis AG has a beta of 0.599, suggesting its less volatile than the S&P 500 by 40.101%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.46%. Novartis AG offers a yield of 3.37% to investors and pays a quarterly dividend of $3.99 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Novartis AG pays out 63.85% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Roche Holding AG quarterly revenues are --, which are smaller than Novartis AG quarterly revenues of $13.6B. Roche Holding AG's net income of -- is lower than Novartis AG's net income of $3.6B. Notably, Roche Holding AG's price-to-earnings ratio is 28.67x while Novartis AG's PE ratio is 18.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus 4.48x for Novartis AG. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer has a net margin of -- compared to Roche Holding AG's net margin of 21.63%. Roche Holding AG's return on equity of 23.8% beat Pfizer's return on equity of 8.72%.

Roche Holding AG has a consensus price target of $46.42, signalling upside risk potential of 15.46%. On the other hand Pfizer has an analysts' consensus of $29.23 which suggests that it could grow by 18.77%. Given that Pfizer has higher upside potential than Roche Holding AG, analysts believe Pfizer is more attractive than Roche Holding AG.

Roche Holding AG has a beta of 0.456, which suggesting that the stock is 54.358% less volatile than S&P 500. In comparison Pfizer has a beta of 0.582, suggesting its less volatile than the S&P 500 by 41.783%.

Roche Holding AG has a quarterly dividend of $1.39 per share corresponding to a yield of 3.46%. Pfizer offers a yield of 6.91% to investors and pays a quarterly dividend of $0.43 per share. Roche Holding AG pays 92.43% of its earnings as a dividend. Pfizer pays out 118.44% of its earnings as a dividend. Roche Holding AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Pfizer's is not.

Roche Holding AG quarterly revenues are --, which are smaller than Pfizer quarterly revenues of $13.7B. Roche Holding AG's net income of -- is lower than Pfizer's net income of $3B. Notably, Roche Holding AG's price-to-earnings ratio is 28.67x while Pfizer's PE ratio is 17.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Roche Holding AG is 3.68x versus 2.25x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.